Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2026 – 6 PM CET Disclosure of a transparency notification from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from BlackRock, Inc., dated 24 September 2026. Notification from BlackRock, Inc. On 25 September 2026, Fagron received a transparency notification from BlackRock, Inc. informing the Company
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 21 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 43,920 new shares have been issued on 21 September 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,764,714.08. The total number of shares with voting rights after the issue amounts
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 July 2026 – 7:00 AM CET Fagron delivers strong H1 2026 performance with 16% topline growth and reiterates FY 2026 guidance Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2026. Key Highlights Revenue up 16.0% to €552.5 million (17.5% at CER), with organic growth of 3.1% at CER, led by EMEA and Latin America and supported by contributions fr
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.